Recent Updates
Recently added Catalysts
JAGX Positive Sentiment

Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates

Tuesday, August 18, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Jaguar Health, Inc. announced an investor webcast scheduled for August 19, 2026, to discuss its Q2 2026 financials and corporate updates. The company plans to file its Earnings Report on Form 10-Q for the quarter ending June 30, 2026. This initiative reflects the company's commitment to keeping investors informed.
Price reaction · baseline $13.1835 (2026-08-17 close) · hit pre-market · 1 other JAGX headline(s) in the window, move may be shared
day 0 close · peak
+11.1%
day 1
+5.2%
day 3
-1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Jaguar Health is actively engaging with investors.
  • The upcoming webcast indicates transparency in financial reporting.
  • The company is preparing to file its Q2 2026 Earnings Report.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+97%
120-day peak, hindsight
Typical move
9.2%
average across 2 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
Crofelemer
Phase 2 · Microvillus Inclusion Disease

Full Press Release Details

Company plans to file its Earnings Report on August 19, 2026 on Form 10-Q for the quarter ended June 30, 2026 SAN FRANCISCO, CA / ACCESS Newswire / August 18, 2026 / Jaguar Health, Inc. ( NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Wednesday, August 19, 2026 at

Frequently Asked Questions

When is the Jaguar Health investor webcast scheduled?

The investor webcast is scheduled for August 19, 2026.

What will be discussed in the webcast?

The webcast will cover Q2 2026 financials and corporate updates.

What report will Jaguar Health file?

Jaguar Health plans to file its Earnings Report on Form 10-Q.

What quarter does the Earnings Report cover?

The Earnings Report covers the quarter ended June 30, 2026.

ShareAdd on Google
Tags: JAGX Jaguar Health investor webcast Q2 2026 financials corporate updates
Last updated: Aug 18, 2026

Biotech snapshot

Cash runway
$4M liquidity · $2M/mo burn
~1 mo
High dilution risk
Lead asset
CrofelemerPhase 2
Microvillus Inclusion Disease →

Catalyst track record

+97%
best trade around JAGX's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for JAGX.

See every catalyst's timing & PoA →